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A B S T R A C T
Graphene has a promising future in applications such as disease diagnosis, cancer therapy, drug/gene delivery,
bio-imaging and antibacterial approaches owing to graphene's unique physical, chemical and mechanical
properties alongside minimal toxicity to normal cells, and photo-stability. However, these unique features and
bioavailability of graphene are fraught with uncertainties and concerns for environmental and occupational
exposure. Changes in the physicochemical properties of graphene aﬀect biological responses including reactive
oxygen species (ROS) production. Lower production of ROS by currently available theranostic agents, e.g.
magnetic nanoparticles, carbon nanotubes, gold nanostructures or polymeric nanoparticles, restricts their clin-
ical application in cancer therapy. Oxidative stress induced by graphene accumulated in living organs is due to
acellular factors which may aﬀect physiological interactions between graphene and target tissues and cells.
Acellular factors include particle size, shape, surface charge, surface containing functional groups, and light
activation. Cellular responses such as mitochondrial respiration, graphene-cell interactions and pH of the
medium are also determinants of ROS production. The mechanisms of ROS production by graphene and the role
of ROS for cancer treatment, are poorly understood. The aim of this review is to set the theoretical basis for
further research in developing graphene-based theranostic platforms.
1. Introduction
Cancer is one of the leading causes of morbidity and mortality
worldwide, with more than 14 million new cases and 8.8 million deaths
in 2012 [1]. Globally, cancer accounts for nearly one of every six
deaths. Cancer elicits a signiﬁcant economic cost. The total annual
economic cost of cancer in 2010 was estimated at approximately US$
1.16 trillion [2]. Conventional therapeutic options including che-
motherapy and radiation therapy are most commonly used in the
treatment of cancer. However, these modalities yield low success rates
and have profound adverse side eﬀects on patients' physical and mental
health [3]. Therefore less invasive, and more eﬀectively targeted,
treatments need to be developed for palliative care and improvement of
quality of life. Novel regimes for simultaneous diagnosis and therapy,
known as theranostics, have changed the cancer treatment algorithm by
the combination of bio-imaging with site-speciﬁc and site-selective
targeting of tumors, without damaging normal cells [4]. A schematic
representation of the components of a typical theranostic platform is
given in Fig. 1.
The two key components of this theranostic platform are: ﬁrst,
targeted diagnostic imaging modalities and, secondly, targeted delivery
of therapies such as photodynamic therapy (PDT). An excellent review
of targeted diagnostic imaging has recently been contributed by Cope
et al. (2016) [5]. PDT has evolved into a practical, eﬀective and sys-
tematic theranostic option comprising of the multiple-exposure, guided,
non-invasive, treatment of tumors in combination with real-time de-
tection and tracking of malignant tissue by ﬂuorescence imaging. The
basis of PDT is that light is utilized to activate a non-toxic photo-
sensitizer, leading to the generation and localization of highly toxic
reactive oxygen species (ROS) at the targeted site of cancerous tissue.
PDT oﬀers several advantages over traditional treatment options, ty-
pically including low toxicity of the photosensitizer in the absence of
light interaction/irradiation, better eﬃcacy, low side eﬀects, selective
and speciﬁc accumulation, and deep penetration of photosensitizer into
the tumors [6]. Nevertheless, the mechanism of the selective and spe-
ciﬁc killing of tumor cells by ROS remains unclear. A better
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understanding of this phenomenon will empower patients and clin-
icians with a greater conﬁdence in this treatment option.
A key feature of PDT is to exploit the light source for selective ac-
tivation of the photosensitizer within the tumor cells. A light source of
appropriate wavelength (visible or near-infrared) is used to activate a
photosensitizer that generates and releases ROS, for the selective killing
of tumors [7]. The photo-activation of the photosensitizer initially en-
ables its excitation to a triplet state through a short-lived intermediate
called the ‘singlet state’. The electron and energy transfer to the sur-
rounding free oxygen produces ROS, including singlet oxygen, the su-
peroxide anion radical, the hydroxyl radical, and hydrogen peroxide.
Highly toxic ROS cause tumor cell death by oxidative stress.
Historically, the development of photosensitizers has resulted in
three eminent generations of photosensitizer types. The ﬁrst generation
is porphyrins [8]. The clinical limitations of porphyrins are poor se-
lectivity, poor photosensitivity, a low clearance rate, and a low light
penetration within tumors. The second generation of photosensitizers -
including chlorins, porphyrinoids and transition metal complexes - also
has several problems such as: high hydrophobicity, poor tumor se-
lectivity, complex surface chemistry, and aggregation in aqueous
media. The third generation includes biomolecule conjugates and
covalently attached peptides [8]. The selection of biomolecules is cri-
tical for their clinical eﬃcacy because of the selective targeting cap-
ability, the structural and photochemical properties of these conjugates,
Fig. 1. Schematic representation of a typical theranostic platform
for the combined use of a range of imaging and therapeutic ap-
proaches. Imaging modalities include: ultrasonography, positron
electron tomography, ﬂuorescence imaging, magnetic resonance
imaging and single-photon emission computed tomography.
Therapeutic approaches include: drug delivery, photothermal
therapy, photodynamic therapy, or a combination of two thera-
pies. Based on its unique properties, graphene can be employed as
a theranostic agent that combines the capabilities of diverse
imaging and therapeutic modalities to target tumors.
Fig. 2. Summary of structural models of various derivatives of graphene. (a) Graphene, (b) graphene oxide (GO), (c) reduced graphene oxide, (d) porous graphene, (e) graphene quantum
dots and (f) three dimensional graphene foam. Graphene is a sp2 hybridized model of carbon atoms in a repeated manner, forming a regular lattice structure (as shown in panel a), while
GO and reduced GO have functional groups and defects in their basal planes (panels b and c). The physicochemical properties and structures of diﬀerent graphene variants depend on the
fabrication method and conditions. The presence of both defects and functional groups provides potential advantages for the eﬃcient utilization of graphene variants in the production of
ROS. The chemical exfoliation method is thought to be an eﬃcient route for synthesizing graphene on a large scale and at low cost. Porous graphene is a graphene sheet that is missing
carbon atoms from its plane. The various forms of porous graphene provide fascinating materials for biological applications owing to their high speciﬁc surface areas, hydrophobic nature
and biocompatibility. Graphene nanopores usually have pore sizes of 1–30 nm. Pores and vacancies can clearly be seen in the porous graphene sheet, as represented in panel (d).
Graphene quantum dots are luminescent nanocrystals having a size less than 50 nm. These have attractive properties and potential applications in cancer diagnosis and treatment. Water
soluble graphene quantum dots, shown in panel (e), have functional groups (C–OH, C=O, C–O–C, C–H) on their surface. Three-dimensional graphene networks in the form of a foam,
sponge or aerogel have recently been assembled from individual graphene sheets using chemical vapour deposition templated methods, which also preserve the unique properties of
individual graphene sheets. [Panel (f) is adapted from [12], with permission of MDPI Publishing Group, Copyright 2015].
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and the degree of receptor expression in the targeted tumors.
Recently, novel photosensitizers have been fabricated to improve
the selective tissue penetration of incident light, and to improve the
clinical eﬃcacy of PDT. Among such novel developments, graphene has
also recently been fabricated and utilized as a photosensitizer and
theranostic agent [9]. Graphene is a two-dimensional single-layer-thin
material with sp2-bonded carbon atoms packed into a honeycomb lat-
tice. This material has gained signiﬁcant attention in many disciplines
of life science, owing to its electronic, optical and structural properties.
Graphene has been applied as a drug carrier in chemotherapy, and as a
Fig. 3. Schematic illustration of the potential mechanisms by which reactive oxygen species (ROS) are associated with the cellular toxicity of graphene. Graphene may aﬀect biological
behavior at the cellular, subcellular, protein and gene levels. The toxicity of graphene depends on its physicochemical interactions and its accumulation in speciﬁc organs. Uptake of
graphene into speciﬁc organs also aﬀects cell function as a result of cellular changes within the organs. The deposition, distribution and clearance of graphene after entering into a living
system is a major knowledge gap in understanding the toxicity of graphene. Graphene circulating in the bloodstream is internalized into cells through the plasma membrane. The plasma
membrane is a selectively permeable membrane that transfers materials such as ions and nano-sized proteins. Graphene (depending on its size, shape, and surface chemistry) enters the
cell via diﬀerent pathways such as clathrin/caveolar-mediated endocytosis, phagocytosis, macropinocytosis, and pinocytosis and exits the cell via the pathways of lysosome secretion,
vesicle-related secretion, and non-vesicle-related secretion. The nature of plasma membrane interaction with graphene determines the fate of graphene in a wide range of potential
applications with high biocompatibility, including drug- and gene-delivery, photothermal and photodynamic therapy. This interaction may lead to the possibility of events such as
adsorption or incorporation of graphene onto the surfaces of cells. Furthermore, the entrapped biomolecules on the surface of graphene, when graphene is present within the extracellular
matrix, may inﬂuence the tertiary structure of a protein - resulting in the formation of a protein-graphene interface and malfunction. The extracellular mechanisms causing the
accumulation of graphene in the extracellular matrix and the subsequent eﬀects of graphene on the extracellular matrix remain undeﬁned. Graphene-induced ROS may cause oxidative
stress, loss of cell function, mitochondrial damage, initiation of lipid peroxidation, covalent chemical modiﬁcations of nucleic acids, DNA-strand breaks, induction of gene expression via
the activation of transcription factors, and modulation of inﬂammation via signal transduction - leading to toxicity, cell death and genotoxicity. The speciﬁc minerals in the secondary
antioxidants are being referred to selenium, zinc, molybdenum, iron and copper. The antioxidant defence system is overwhelmed by high levels of ROS, leading to oxidative stress,
inﬂammation and toxicity. One potential way to minimize the toxicity of graphene is to functionalize the graphene with biodegradable agents.
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photosensitizer for photothermal therapy and PDT. A graphene nano-
hybrid showed improved anticancer PDT eﬀects compared to the con-
ventional photosensitizers [10]. Graphene has signiﬁcant potential for
use in theranostic agents due to many fascinating properties, such as a
high speciﬁc surface area, appropriate energy and/or electron transfer
features, a high ﬂuorescence quantum yield, π−π stacking, good water
dispersibility, good biocompatibility, enhanced drug-loading eﬃciency,
selective tumor uptake, minimal side eﬀects and a high yield of ROS
production. Graphene has a variety of derivatives including graphene
oxide (GO), reduced graphene oxide, graphene quantum dots, graphene
nanoribbons, three dimensional graphene foam and graphene nano-
pores. The structural models of several graphene derivatives are shown
in Fig. 2. GO is a highly eﬃcient long-range quencher for various
ﬂuorescence processes [11].
The therapeutic responses of diﬀerent derivatives of graphene such
as GO and graphene quantum dots revealed them as promising treat-
ment agents and showed the possibility of exploiting ROS in cancer
treatment. A better understanding of the role of ROS in the therapeutic
mode of action of graphene, in cancer treatment, will facilitate the
development of improved graphene-based theranostic platforms.
2. Toxic potential of graphene family nanomaterials
ROS generation by nanoparticles has been considered as the pri-
mary source of their toxicity [13]. Potential adverse eﬀects of ROS in-
clude the downregulation of defensive systems to disrupt the structure
and function of normal cells. ROS cause damage to cellular components
such as proteins, DNA and lipids, resulting in the release of in-
ﬂammatory cytokines and chemokines. ROS generation by graphene is
dependent on several factors that strongly deﬁne the extent of gra-
phene-induced toxicity, such as: size and shape, particle surface, surface
charges, surface-associated chemical groups, solubility and dispersion,
ions released from graphene, photo-activation, aggregation, mode of
interaction with cells, the presence of inﬂammation in tissues, and the
pH of the system. In addition, the conditions of experiments in which
graphene is administered, either in vivo or in vitro, aﬀect the interac-
tions between graphene and targeted cells. Such conditions include the
time of exposure, dose, and (in the case of in vitro experiments) the cell
type and the criterion used for examining cell viability. For in vivo
models, the method of administration is also of course crucial [9].
Graphene can cause an inﬂammatory response that produces relatively
large amounts of free radicals such as hydroxyl radicals [14]. GO at a
low concentration (< 4 μg/ml) resulted in a perturbation of mi-
tochondrial structure and function in Hep G2 cells, as measured by a
decrease in the mitochondrial membrane potential and the dysregula-
tion of mitochondrial Ca2+ homeostasis [15], while higher concentra-
tions of graphene quantum dots (< 200 μg/ml) also caused decreases in
the mitochondrial membrane potential by increased ROS generation, in
association with apoptotic and autophagic cell deaths, with an increase
in the expression caspase 3, caspase 9, beclin 1, and microtubule-as-
sociated protein 1A/1B-light chain 3 [16]. Apoptosis and autophagy are
two key modes of cancer cell death, in addition to necrosis. Apoptosis is
a widely studied form of cell death and mainly originates through the
activation of death receptors (extrinsic pathway) or through mi-
tochondrial permeabilization (intrinsic pathway). ROS play a key role
in both the extrinsic and intrinsic pathways of apoptosis, as initiators
and in enabling signaling events. The apoptosis-inducing ligand, Fas,
produces ROS in the extrinsic pathway of the apoptotic process [17].
Activation of the extrinsic pathway requires an inﬂammatory response
to tissue injury and may cause a delay in intrinsic pathway initiation
that responds immediately to calcium and ROS. Oxidative stress may be
associated with the intracellular accumulation of ROS. Moreover, in-
creased intracellular ROS levels, with associated increases in apoptosis,
were detected in murine RAW 264.7 macrophages exposed to graphene
(20–100 µg/ml) [18]. Chang et al. [19] reported a concentration-de-
pendent toxicity of GO on A549 cells in vitro, a concentration of
200 µg/ml causing a dose-dependent oxidative stress in cells and in-
ducing a loss of cell viability. However it was also found that a low
concentration of GO (10 μg/ml) did not enter A549 cells and had no
obvious toxicity. The higher concentration of GO (200 µg/ml) caused
oxidative stress and induced a slight loss of cell viability. Oxidative
stress as a result of graphene-cell interactions may cause cell muta-
genesis, carcinogenesis and ageing [20]. Graphene may cause mi-
tochondrial toxicity that includes changes in mitochondrial calcium
levels and depletion of the mitochondrial membrane potential. Gra-
phene subsequently triggers apoptosis by the activation of mitochon-
drial pathways, namely the mitogen-activated protein kinases (MAPKs)
and transforming growth factor-β (TGF-beta)-related signaling path-
ways. Graphene has the potential to adsorb aromatic amino acids by π-
π stacking [21]. Recent in vivo and in vitro studies [12,14–20,22,23]
have shown the role of ROS in mediating the toxicity of graphene. A
schematic illustration of the potential ROS-mediated mechanisms
Fig. 4. Cell signaling and molecular targets of ROS in
cancer. ROS may induce both transcriptional factors/
activators and genes associated with tumor sup-
pression: HIF-1α (hypoxia-inducible factor-1 alpha);
NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells); PTEN (phosphatase and tensin
homolog deleted on chromosome 10); AP-1 (acti-
vator protein-1); Hh (hedgehog protein); STAT3
(signal transducer and activator of transcription 3);
Rb (retinoblastoma protein); Nrf2 (nuclear factor
(erythroid-derived 2)-like 2); Sp1 (speciﬁcity protein
1). NF-κB and AP-1 are transcription factors that play
key roles in the expression of many genes involved in
inﬂammation as well as many other signiﬁcant
events such as embryonic development, lymphoid
diﬀerentiation and apoptosis. HIF-1α plays an es-
sential role in embryonic vascularization and tumor
angiogenesis. Nrf2, a redox-sensitive transcription
factor, regulates genes which bind antioxidant re-
sponse elements in DNA. PTEN is a tumor suppressor
gene, which is deleted or mutated at high frequency
in a large number of cancers. Rb protein is a tumor
suppressor gene which controls cell cycle progres-
sion. Sp1 is a transcription factor which contributes
to overexpression of MDM2 (mouse double minute 2 homolog) in rhabdomyosarcoma tumors. Stat 3 is a transcription factor which plays an important role in cell growth and apoptosis.
ROS-mediated signaling through activation of these transcription factors controls the expression of genes involved in inﬂammation, metastasis, cell proliferation and tumor angiogenesis,
as well as tumor cell death or survival.
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Fig. 5. Schematic representations of the mechanism involved in singlet oxygen production leading to programmed cell death induced by combined photodynamic and photothermal
therapies using a graphene nanocomposite photosensitizer. Photodynamic therapy (PDT) refers to the use of a non-toxic compound called a photosensitizer and a special laser light to kill
cancer cells, while photothermal therapy (PTT) uses the heat generated from the absorbed optical energy by light-absorbing nanoparticles embedded within tumors to ablate tumor cells.
Panel (a) shows a schematic illustration of the mechanisms of singlet oxygen (1O2) generation by a photosensitizer, in the form of a Jablonski diagram representing the electronic states of
a photosensitizer after light absorption, followed by energy transfer to an oxygen molecule to generate 1O2. The photosensitizer displays intersystem crossing to the triplet state when the
photosensitizer is excited to the singlet state. The electronic states are shown in the diagram. Internal conversion: transitions between states of similar electronic spin, where the
electronic states are singlet and triplet. Fluorescence: the emitted photon has energy resembling the energy diﬀerence between the initial and ﬁnal states of the photosensitizer. The
emitting and ﬁnal states have similar electronic spin states, either singlet or triplet. Intersystem crossing: the change of electronic spin in the excited state, from singlet to triplet.
Phosphorescence: the emitted photon has energy resembling the energy diﬀerence between the initial and ﬁnal states of the photosensitizer. The emitting and ﬁnal states have diﬀerent
electronic spin states, such as one in the singlet state and the other in the triplet state. Panel (b) is a schematic illustration of the mechanism of cancer cell killing induced by a
functionalized hybrid of folic acid (FA), polyethylene glycol (PEG) and C60 (a spherical fullerene molecule with the formula C60 called buckminsterfullerene) non-covalently conjugated to
GO for synergistic combined photothermal therapy and photodynamic therapy. Thus, the functionalized hybrid consists of FA-GO-PEG/C60 [FA (cancer targeting moiety) and C60
(photosensitizer) conjugated to PEGylated graphene oxide]. Functionalized GO was exposed to light sources with wavelengths of 532 and 808 nm for enhanced cellular uptake of C60 in
cancer cells. The GO nanocomposite showed eﬀective cell apoptosis and death and exhibited a synergistic eﬀect of combined photodynamic and photothermal therapies. [Panel (b) is
adapted from [10], with permission of the Royal Society of Chemistry, Inc., Copyright 2015].
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manifested by graphene in the cell is shown in Fig. 3.
3. ROS in cancer theranostics
The proof-of-concept investigations of graphene in cancer ther-
anostics are still at a preclinical stage. An early report on GO as ther-
anostic agent was published by Cho and his group [24]. They synthe-
sized a GO-based photosensitizer with a redox-responsive disulﬁde
linker which was activated by glutathione. This photosensitizer ex-
hibited a remarkable ﬂuorescence emission and singlet oxygen gen-
eration in the presence of glutathione as a reducing agent. There was
eﬃcient cellular internalization and preferential accumulation of the
photosensitizer inside cancer cells, and glutathione was then able to
cleave the disulﬁde linkers. Cho et al. demonstrated in vitro cellular
uptake and ﬂuorescence activation of the photosensitizer, but they did
not report the role of ROS in phototoxicity towards A549 cells. As
mentioned earlier, ascertaining the type of ROS produced, the nature of
intracellular ROS signaling, ROS localization, and cancer cell-speciﬁc
ROS-sensing mechanisms are the most important challenges in relation
to understanding the role of the ROS in cell killing by graphene. The
molecular targets of ROS in cancer are shown in Fig. 4. ROS may induce
both transcription factors/activators and genes associated with tumor
suppression [25].
Cancer cells possess an inherent nature of survival and re-growth
[26]. Thus, the eﬀectiveness of a therapy depends on the selective and
speciﬁc targeting of tumors without producing chronic, severe, harm to
vital organs and normal cells. Caspase activation by the intrinsic
pathway leads to the release of cytochrome c, a family of proteins
known as “inhibitors of apoptosis proteins” (IAP), and endonuclease G.
Release of these factors leads to disintegration of the mitochondrial
membrane to form the mitochondrial permeability transition pore
complex. Cao et al. [27] prepared a multifunctional theranostic agent
based on porphyrin-conjugated polyethylene glycol-functionalized
graphene quantum dots. These functionalized graphene quantum dots
demonstrated a clear discrimination (as observed by the use of a cell
imaging label and intracellular micro RNA detection) of cancer cells
from somatic cells. The functionalized graphene quantum dots also
exhibited a high yield of singlet oxygen (quantum yield up to 1.08) with
28.58% photothermal conversion eﬃciency. Apoptotic events and cell
membrane destruction were observed in A549 cells exposed to these
porphyrin-conjugated polyethylene glycol-functionalized graphene
quantum dots. However, porphyrin-based functionalized graphene
quantum dots revealed a slightly slower 1O2 production rate compared
with porphyrin alone. Wei et al. [28] prepared a nanodrug pyr-
opheophorbide-a-nano GO-monoclonal antibody conjugate, within
which the monoclonal antibody was directed against integrin αvβ3 as a
mechanism for tumor targeting. The authors demonstrated that the
phototoxicity of GO-bound pyropheophorbide can be switched on and
oﬀ in both organic and aqueous environments after the conjugation of
pyropheophorbide with polyethylene-glycol. The functionalized GO
eﬃciently targets the cancer cells’ surface ligand (i.e. integrin αvβ3).
Once endocytozed by the cells, and having then escaped from lyso-
somes, the functionalized GO subsequently moves to the mitochondria.
The two-fold on/oﬀ switching of this functionalized GO considerably
increases the intrinsic pathway of apoptosis.
H2O2-induced apoptosis usually occurs in lymphoma cells via acti-
vation of cysteine proteases such as caspase-3 [29]. H2O2 is a precursor
of highly reactive hydroxyl radicals, while H2O2 itself has relatively low
reactivity. H2O2 produced by nanoparticles has shown great potential
to initiate apoptosis in the cells of osteosarcomas, and in breast,
bladder, and lung cancer cells. He et al. [30] reported a nanoagent
based on iron hydroxide/oxide-modiﬁed GO and showed a higher
generation of superoxide anion radicals under near-infrared light irra-
diation, compared with GO alone. In respect of this composite, it was
proved that near-infrared light irradiation promoted electron transfer
from GO to Fe(III) (endogenously present within the cells) and
accelerated the formation of superoxide radicals. H2O2 (formed from
superoxide) then reacted with Fe(II) and gave an improved yield of
hydroxyl radicals. Excessive generation of ROS is known to trigger
oxidative damage to various biomolecules, such as DNA, proteins and
lipids, which in turn may lead to mitochondrial membrane permeabi-
lization [31]. In some cases, ROS may induce both apoptosis and ne-
crosis in tumors. Qu et al. [32] reported GO-induced macrophagic cell
death through programmed necrosis in J774A.1 cells and showed that
GO toxicity is mediated by activation of toll-like receptor 4 (TLR4)
signaling. Macrophage cell death linked to GO exposure was attributed
to programmed necrosis mediated by a receptor-interacting protein
kinase 1 and 3 complex, downstream of TNF-α induction. Fig. 5a & b
are schematic illustrations of the mechanisms by which photosensitizers
generate 1O2, and by which the hybrid of folic acid polyethylene glycol
and C60 (a spherical fullerene molecule with the formula C60 called
buckminsterfullerene) conjugated to GO (FA-GO-PEG/C60) achieves the
combined synergistic eﬀects of photothermal therapy and PDT.
4. Summary
In summary, recent studies underpinning the application potential
of graphene in the theranostic ﬁeld have been reviewed. Many groups
have utilized graphene in PDT, photothermal therapy and ﬂuorescent
imaging for cancer treatment. The combination of imaging and therapy
could produce synergistic eﬀects to increase the targeted killing with
minimal side eﬀects and with the maintenance of biocompatibility. The
scope for functionalization and conjugation of graphene can potentially
generate a promising array of theranostic agents. Further in vivo studies
will be required to better understand the real-world applications of
graphene. Moreover, the aspects of ROS generation, toxicity and po-
tential cancer theranostic approaches for other derivatives of graphene
such as graphene nanoribbons, graphene nanoplatelets, three dimen-
sional graphene foams, graphene nanopores, and porous graphene na-
nosheets will need to be studied. Oxidative stress induced by graphene
accumulated in living organs is due to acellular factors such as particle
size, particle shape, surface charge, surface functional groups, and light
activation, while cellular responses such as mitochondrial respiration,
immune cell activation, pH of the medium and physiological redox-
regulated functions are critical determinants aﬀecting the production of
ROS. To date, the mechanisms and roles of ROS production by most
forms of graphene in relation to cancer treatment, are not understood. A
basic understanding of graphene-cell interactions (especially ROS gen-
eration), as well as the optimal conditions for their proper use, will
provide new theranostic platforms in the future.
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